(R,S)-Atenolol (Synonyms: Duraatenol,IC I66082,Tenormin®) |
رقم الكتالوجGC12823 |
(R ، S) -Atenolol ((RS) - (R ، S) -Atenolol) عبارة عن حاصرات انتقائية للقلب β ؛ 1-adrenergic receptor blocker ، مع Ki 697 نانومتر atβ ؛ 1-adrenoceptor في غشاء البطين الأيسر لخنزير غينيا.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 29122-68-7
Sample solution is provided at 25 µL, 10mM.
Ki: 1.14 and 48.7 μM for β1 and β2, respectively
(R,S)-Atenolol is a β1-adrenergic receptor antagonist.
Beta-adrenoceptor antagonists are widely used in cardiovascular medicine as well as in the management of anxiety, migraine and glaucoma. The mode of action in cardiovascular disease is from antagonism of endogenous catecholamine responses in the heart.
In vitro: (R,S)-Atenolol was found to differ slightly regarding potency and to be practically equal regarding relative selectivity, while ICI 141,292 had slightly higher relative selectivity and much higher potency. (R,S)-Atenolol exhibited highest affinity for the beta 1-receptor population. In contrast, ICI 118,551 exhibited a very high relative selectivity with highest affinity for the beta 2-receptor subtype [1].
In vivo: The renal effects of (R,S)-atenolol in rats were studied. Results showed that the iv infusion of (R,S)-atenolol increased urinary sodium excretion, urine volume (UV), urinary potassium excretion and urinary chloride excretion. (R,S)-Atenolo intraaortally injected produced an increase in UV and sodium concentration in the urine, inducing a more marked increase in total sodium amount excreted from both kidneys [2].
Clinical trial: In a previous clinical study, the effects of single oral doses of 100 mg (R,S)-atenolol were compared to those of equal amounts of the optically pure enantiomers. The mean rate pressure product decreased with (R,S)-atenolol and half-dosed (S)-atenolol to the same extent, whereas (R)-atenolol caused no effect. Radioligand binding studies in beta-adrenergic receptors yielded a eudismic ratio of 46 for (S)- to (R)-atenolol. It was conclude that only (S)-atenolol, but not (R)-atenolol, contributed to the beta-blocking effect (R,S)-atenolol since the same effect can be elicited with the (S)-enantiomer alone [3].
References:
[1] Golf, S. ,Bjornerheim, R.,Erichsen, A., et al. Relative selectivity of different β-adrenoceptor antagonists for human heart β1- and β2-receptor subtypes assayed by a radioligand binding technique. Scandinavian Journal of Clinical and Laboratory Investigation 47(7), 719-723 (1987).
[2] Yamazaki N, Monma Y, Tanabe T. Effects of propranolol and atenolol on the rat kidney. Nihon Yakurigaku Zasshi. 1983 May;81(5):333-42.
[3] Stoschitzky K, Egginger G, Zernig G, Klein W, Lindner W. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality. 1993;5(1):15-9.
Cas No. | 29122-68-7 | SDF | |
المرادفات | Duraatenol,IC I66082,Tenormin® | ||
Chemical Name | 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-benzeneacetamide | ||
Canonical SMILES | NC(CC1=CC=C(OCC(O)CNC(C)C)C=C1)=O | ||
Formula | C14H22N2O3 | M.Wt | 266.3 |
الذوبان | ≥ 9.1mg/mL in Water with gentle warming | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.7552 mL | 18.7758 mL | 37.5516 mL |
5 mM | 0.751 mL | 3.7552 mL | 7.5103 mL |
10 mM | 0.3755 mL | 1.8776 mL | 3.7552 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 33 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *